Adc Therapeutics Sa ADCT

$1.44 +0.04 (2.86%)

Valuation

Market cap
178,735,000
Revenue TTM
$81,360,000
Net income TTM
$-142,620,000
PE ratio
0.00
Forward PE
—
Profit margin
-175.30%
Debt to equity
-0.51

Trading

Volume
575,620
Avg volume
1,723,068
Day's range
$1.39 – $1.49
Shares out
127,668,000
Stochastic %K
32%
Beta
1.86
Analysts
Sell
Price target
$3.33

Price

Company profile

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or ref...

Show more

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
41 21 653 02 00
Website
https://www.adctherapeutics.com
Address
BiopOle, Route de la Corniche 3B, Epalinges, Switzerland

Latest news

Stocktwits

Merlintrader Oct 16, 11:49 AM
$ADCT Latest company news, October 8, 2026: ADC Therapeutics $ADCT announced an $86.6 million private placement expected to close October 22, new HCR royalty terms and a smaller secured loan, extending expected cash runway into 2029. LOTIS-7 and MZL data are due at ASH in December. Full hub (ZYNLONTA, FDA concerns on LOTIS-5, dilution): https://www.merlintrader.com/adc-therapeutics-adct-stock-hub/ Not investment advice.
0 replies
Spartrap Oct 13, 1:07 PM
$ADCT 21M preliminary 3rd Q net sales is encouraging btw +33% y-o-y, +13% q-o-q
0 replies
JuggernautRaider Oct 12, 4:14 PM
$ADCT hmm new jersey 💯
0 replies
TNNStockAnalysisNews Oct 12, 2:42 AM
Stocks Under $3 to Watch Tomorrow, Oct 12, 2026: $PDSB From $0.70 to $1.40: The Oncology Name That Keeps Reloading $QSI 19 of 20 Amino Acids $QTEX A Nasdaq Notice Meets a Six-Day Streak Above $1 $NAUT A $286 Million Proteomics Name Doubles in October $ADCT $86.6 Million PIPE Extends Cash to 2029 https://truthsandnews.com/markets/stocks-under-3-to-watch-tomorrow-oct-12-2026-penny-stocks
0 replies
fmalad Oct 9, 6:56 PM
$ADCT what does Bain capital do for a living? They help finance companies then help sell them. Roche is the likely suitor!
0 replies
KryptonResearch14 Oct 9, 5:03 PM
$ADCT ADC Therapeutics announced a three-part capital fix Thursday: an 86.6 million PIPE (12.9 million shares at 1.42, warrants for 48.1 million more at 1.32, closing around Oct 22), a senior-loan paydown leaving 50 million due August 2029 with no liquidity covenant, and a HealthCare Royalty amendment killing the 150 million payment that would have triggered on any takeover. The change-of-control removal is doing the real work. That 150 million was a takeover tax baked into the capital structure. Stripping it while Bain Capital Life Sciences writes a fresh check keeps ADC independent into the November data reads (LOTIS-7 and MZL abstracts, ASH in December) instead of selling into the LOTIS-5 overhang. The context: the FDA flagged benefit-risk concerns on the LOTIS-5 combo trial back in August, and the company cut about 17 percent of staff. Runway now stretches into 2029. Shares up about 10 percent Friday to around 1.75.
0 replies
Kosmokrat Oct 9, 4:25 PM
$ADCT Wow, it feels so good to see a stock skyrocketing that you actually own. I still hope for a big bang once the LOTIS-7 results are out, but I don't mind the recent run-up at all. What also caught my eye: In yesterday's financial restructuring news they also mentioned they removed the "change of control" payment in the HCR agreement. Which means they are now making it easier for a 3rd party to acquire them without penalty. Maybe that is what's coming next?
0 replies
topstockalerts Oct 8, 8:43 PM
$ADCT what looked ordinary this morning no longer does.
0 replies